Pharmaceuticals Industry Annual Growth to hit US$ 3,178.63 Billion by 2033: M & A, Drug Approvals, Investment Growth | Top 5 Companies are Pfizer Inc, Novo Nordisk A/S, AstraZeneca, GSK plc, Merck KGaA

global pharmaceuticals market size reached US$ 1,740.44 Billion in 2024 from US$ 1,635.82 Billion in 2023 and is expected to reach US$ 3,178.63 Billion by 2033, growing at a CAGR of 7.0% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/pharmaceutical-market?kb

United States: Recent Industry Developments

✅ October 2025: Pfizer launched a novel gene therapy targeting rare genetic disorders, marking a milestone in precision medicine.

✅ September 2025: Johnson & Johnson expanded its pipeline with new immuno-oncology candidates entering late-stage trials.

✅ August 2025: FDA approved several breakthrough drugs accelerating treatments for autoimmune and neurodegenerative diseases.

Japan: Recent Industry Developments

✅ October 2025: Takeda Pharmaceutical developed next-generation oral formulations improving patient adherence and bioavailability.

✅ September 2025: Astellas Pharma initiated collaborations focusing on regenerative medicine and cell therapy innovations.

✅ August 2025: Ongoing clinical trials in Japan emphasized personalized medicine approaches in oncology and rare diseases.

Latest M&A

Johnson & Johnson acquired Halda Therapeutics for $3.05 billion, expanding its oncology and rare disease drug portfolio.​

Merck & Co., Inc. agreed to acquire Verona Pharma for $10 billion, enhancing its cardio-pulmonary and respiratory portfolio.​

Novartis AG is expanding U.S. manufacturing capacity with two new sites in North Carolina as part of its $23 billion U.S. onshoring initiative.​

Eli Lilly and Company announced a $1 billion manufacturing and quality hub investment in Hyderabad, strengthening its global supply chain.

Key Players:

Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Pfizer Inc., AbbVie Inc., AstraZeneca, Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi, Novo Nordisk A/S, GSK plc, Amgen Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Gilead Sciences, Inc., Bayer AG, Merck KGaA, and Teva Pharmaceutical Industries Ltd.

Latest Investments

Globally, pharmaceutical M&A reached nearly $70 billion in 2025, with continued investor interest in biotech and specialty pharma fueling innovation.​

Moderna is investing heavily in mRNA manufacturing expansions globally, including a $140 million facility in Norwood, Massachusetts.​

Indian pharmaceutical firms also witnessed significant funding rounds, aligning with increased domestic and international demand.

Growth Forecast Projection:

The Global Pharmaceuticals Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Pharmaceuticals Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=pharmaceutical-market?kb

Key Segmentation:

By Type: (Prescription Drugs and Over-the-Counter (OTC) Drugs)

By Drug Type: (Branded Drugs and Generic Drugs)

By Therapeutic Area: (Cardiovascular Diseases, Oncology, Neurology, Respiratory Diseases, Endocrine & Metabolic Diseases, Gastrointestinal Disorders, Musculoskeletal Disorders, Dermatology Disorders and Others)

By Route of Administration: (Oral, Topical, Parenteral, Inhalations and Others)

By Distribution Channel: (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

Project Hubs

Hyderabad is emerging as an important pharmaceutical manufacturing and R&D hub, with investments from Eli Lilly and other global pharma companies boosting capacity and innovation.​

North Carolina hosts new manufacturing facilities for Novartis as part of onshoring efforts.

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/pharmaceutical-market?kb

Latest Clinical Trials

Active trials include phase 3 studies on breast cancer immunotherapies, anti-inflammatory drugs, and rare disease treatments in various global locations.​

Kelun Biotech announced positive topline results from phase 3 trials of an oral FXIa inhibitor (asundexian) targeting ischemic stroke risk reduction.

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/pharmaceutical-market?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.